Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
基本信息
- 批准号:8685149
- 负责人:
- 金额:$ 30.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-21 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAgonistAntigen PresentationAntigensBindingBiologicalBreast CarcinomaCTLA4 geneCancer VaccinesCellsCellular ImmunityCombined VaccinesComplexCross PresentationDendritic CellsHeat shock proteinsHyperthermiaImmuneImmunityImmunotherapyInflammationIonizing radiationLeadMammary NeoplasmsMediatingMusNatural ImmunityNeoplasm MetastasisPathway interactionsPopulationPropertyProtein BindingProteinsRadiationRadiation therapyRegulationResistanceRoleSignal TransductionStructure-Activity RelationshipT-Cell ActivationT-LymphocyteTLR3 geneToll-like receptorsTranslatingTreatment EffectivenessTumor ImmunityVaccine DesignVaccinesbasecancer therapyextracellularhuman TLR3 proteininhibitor/antagonistkillingsmalignant breast neoplasmneoplastic cellnovel vaccinesprogramsreceptortranslational studytumoruptakevaccine effectiveness
项目摘要
DESCRIPTION (provided by applicant): Extracellular heat shock proteins (HSP) have been shown to have a profound effect on tumor immunity. We have prepared a highly effective cancer vaccine by extracting Hsp70/Hsp90 complexes from the fusion of tumor cells and dendritic cells (Hsp70.PC-F). We aim in this proposal to examine the properties of the vaccine and optimize its use either solo or combined with ionizing radiation. We aim first to understand the role of the receptor SRECI in dendritic cells (DC) in binding to Hsp70.PC-F and subsequent uptake and presentation of antigens to T lymphocytes. We aim to determine how SRECI can orchestrate antigen cross presentation, innate immune stimulation and cell regulation in DC. Next, in the translational studies in Aim 2 we will examine the role of Hsp70.PC-F in treatment of spontaneous mammary carcinoma in mice. We aim to determine treatment effectiveness and the degree to which vaccines can be used in combination with adjuvants such as TLR3 and TLR9 agonists as well as inhibitors of co-repressing molecule CTLA4. We will further determine whether vaccine design can be manipulated to give selective destruction of tumor initiating cells and radiation resistant cells that accumulate in fractionated radiation therapy.
描述(由申请人提供):细胞外热休克蛋白(HSP)已被证明对肿瘤免疫有深远的影响。我们从肿瘤细胞与树突状细胞融合中提取Hsp70/Hsp90复合物(Hsp70. pc - f),制备了高效的肿瘤疫苗。我们在这项建议中旨在检查疫苗的性质,并优化其单独使用或与电离辐射结合使用。我们的目标首先是了解树突状细胞(DC)中受体SRECI与Hsp70结合的作用。PC-F和随后的抗原摄取和递呈到T淋巴细胞。我们的目标是确定SRECI如何在DC中协调抗原交叉呈递、先天免疫刺激和细胞调节。接下来,在Aim 2的翻译研究中,我们将研究Hsp70的作用。PC-F对小鼠自发性乳腺癌的治疗作用。我们的目标是确定治疗效果和疫苗可与佐剂(如TLR3和TLR9激动剂)以及共抑制分子CTLA4抑制剂联合使用的程度。我们将进一步确定疫苗设计是否可以被操纵来选择性地破坏肿瘤起始细胞和放射抵抗细胞,这些细胞在分次放射治疗中积累。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART Keith CALDERWOOD其他文献
STUART Keith CALDERWOOD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART Keith CALDERWOOD', 18)}}的其他基金
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
8537837 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
8394481 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
8870305 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
7499016 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
7386932 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
7880266 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
Extracellular Hsp70 and hyperthermia in tumor therapy
肿瘤治疗中的细胞外 Hsp70 和热疗
- 批准号:
8115185 - 财政年份:2007
- 资助金额:
$ 30.13万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)